Zobrazeno 1 - 10
of 5 488
pro vyhledávání: '"sglt2 inhibitor"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipraglifloz
Externí odkaz:
https://doaj.org/article/c8f7851be87649e49f1166c1f49d57a8
Autor:
Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1211-1219 (2024)
ABSTRACT Aims/Introduction Insulin resistance syndrome and lipoatrophic diabetes are rare conditions characterized by the development of treatment‐refractory diabetes with severe insulin resistance. We recently conducted a 24 week, multicenter, sin
Externí odkaz:
https://doaj.org/article/d60e2f3c3183423c9437d2a067c99250
Autor:
Jiaqi Mei, Yi Li, Liyan Niu, Ruikai Liang, Mingyue Tang, Qi Cai, Jingdong Xu, Deju Zhang, Xiaoping Yin, Xiao Liu, Yunfeng Shen, Jianping Liu, Minxuan Xu, Panpan Xia, Jitao Ling, Yuting Wu, Jianqi Liang, Jing Zhang, Peng Yu
Publikováno v:
Translational Neurodegeneration, Vol 13, Iss 1, Pp 1-16 (2024)
Abstract The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, are increasingly stu
Externí odkaz:
https://doaj.org/article/cb6395b5728842fd94ce981f3e3ddf45
Autor:
Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Katriona Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, Kenneth Mangion, Patrick B. Mark, Alex McConnachie, John J.V. McMurray, Barbara Meyer, Vanessa Orchard, Aadil Shaukat, Stuart Watkins, Paul Welsh, Naveed Sattar, Colin Berry, Kieran F. Docherty
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2001-2012 (2024)
Abstract Aims Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The earl
Externí odkaz:
https://doaj.org/article/2392cabc2be74029819f96fb1ade1e0f
Autor:
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 1875-1879 (2024)
Abstract Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Stan
Externí odkaz:
https://doaj.org/article/7b8685721c094d3f8713fa148d206e05
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-14 (2024)
Abstract Background Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2
Externí odkaz:
https://doaj.org/article/cc533448d7aa46769f24c41e9b4e368e
Autor:
Qi Gao, Yingying Jiang, Zhenqiang Song, Huizhu Ren, Yan Kong, Cong Wang, Miaoyan Zheng, Chunyan Shan, Yanhui Yang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Lipid peroxidation and mitochondrial damage impair insulin sensitivity in skeletal muscle. Sirtuin-1 (SIRT1) protects mitochondria and activates under energy restriction. Dapagliflozin (Dapa) is an antihyperglycaemic agent that belongs to th
Externí odkaz:
https://doaj.org/article/f864967b1e704871a9f4f74eab9f24c3
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While
Externí odkaz:
https://doaj.org/article/6e17f767eae44338b0347bb08197d2ba
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Renal outcomes in patients with type 2 diabetes following treatment with sodium–glucose co-transporter-2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP1RAs) have not been directly compared. This study com
Externí odkaz:
https://doaj.org/article/4e85355979f1434fb1f87ffca4ddb65b
Publikováno v:
Case Reports in Nephrology and Dialysis, Vol 14, Iss 1, Pp 81-87 (2024)
Introduction: Emphysematous pyelonephritis is a rare but potentially life-threatening urinary tract infection characterized by the formation of gas in the renal parenchyma, collecting system, and perinephric tissue. The condition typically develops i
Externí odkaz:
https://doaj.org/article/d5c44cc3b378465ca776341e776d2bf4